NEISSERIA MENINGITIDIS SEROGROUP B

Clinical trials for NEISSERIA MENINGITIDIS SEROGROUP B explained in plain language.

Never miss a new study

Get alerted when new NEISSERIA MENINGITIDIS SEROGROUP B trials appear

Sign up with your email to follow new studies for NEISSERIA MENINGITIDIS SEROGROUP B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

First human tests begin for Next-Generation meningitis shot

⭐️ VACCINE ⭐️ Not yet recruiting

This early-stage study aims to test the safety and immune response of a new vaccine (DX-104) designed to protect against meningitis B. It will involve 30 healthy adults aged 18-50, who will receive three shots over six months. The new vaccine's safety and ability to trigger prote…

Matched conditions: NEISSERIA MENINGITIDIS SEROGROUP B

Phase: PHASE1 • Sponsor: Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) • Aim: ⭐️ VACCINE ⭐️

Last updated Mar 30, 2026 14:32 UTC

NEISSERIA MENINGITIDIS SEROGROUP B

Get alerted when new NEISSERIA MENINGITIDIS SEROGROUP B trials appear

First human tests begin for Next-Generation meningitis shot